{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:11:38Z","timestamp":1788930698119,"version":"build-2803163510"},"reference-count":79,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370198"],"award-info":[{"award-number":["82370198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Peripheral T\u2010cell lymphoma (PTCL) is a heterogeneous group of aggressive malignancies with poor prognosis and limited response to standard chemotherapy. Although recent advances in molecular and biological characterization have refined PTCL classification, profound molecular heterogeneity continues to result in highly variable treatment outcomes. Emerging targeted and immunotherapeutic agents show activity in specific subtypes, yet responses remain difficult to predict amid their biological complexity. This review synthesizes current molecular insights, evaluates the limitations of existing therapies, and explores the potential of multi\u2010omics profiling integrated with artificial intelligence (AI) to decode complex signatures for improved subtype classification, treatment response prediction, and survival prognostication. By addressing the \u201cblack\u2010box\u201d issue through explainable AI, this approach offers a promising framework to advance PTCL management from empirical treatment toward biomarker\u2010driven precision therapy.<\/jats:p>","DOI":"10.1111\/ejh.70313","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:56:45Z","timestamp":1788929805000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational Insights From the Molecular Landscape to Precision Therapy in Peripheral T\u2010Cell Lymphoma: Integrating Multi\u2010Omics and Artificial Intelligence"],"prefix":"10.1111","author":[{"given":"Qiuyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-0840","authenticated-orcid":false,"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"8","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.26270","article-title":"Aggressive T\u2010Cell Lymphomas: 2021 Updates on Diagnosis, Risk Stratification and Management","volume":"96","author":"Zain J. M.","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"3","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12185-014-1520-3","article-title":"Peripheral T Cell Lymphoma in Asia","volume":"99","author":"Park S.","year":"2014","journal-title":"International Journal of Hematology"},{"issue":"10","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real\u2010World Data on Prognostic Factors and Treatment in Peripheral T\u2010Cell Lymphomas: A Study From the Swedish Lymphoma Registry","volume":"124","author":"Ellin F.","year":"2014","journal-title":"Blood"},{"issue":"7","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R.","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report From the Clinical Advisory Committee","volume":"140","author":"Campo E.","year":"2022","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI\u2010Driven Multi\u2010Omics Integration in Precision Oncology: Bridging the Data Deluge to Clinical Decisions","volume":"26","author":"Hsu C. Y.","year":"2025","journal-title":"Clinical and Experimental Medicine"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.csbj.2021.06.030","article-title":"Integration Strategies of Multi\u2010Omics Data for Machine Learning Analysis","volume":"19","author":"Picard M.","year":"2021","journal-title":"Computational and Structural Biotechnology Journal"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1425456","article-title":"Methods for Multi\u2010Omic Data Integration in Cancer Research","volume":"15","author":"Hernandez\u2010Lemus E.","year":"2024","journal-title":"Frontiers in Genetics"},{"issue":"1","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad453","article-title":"Explainable Artificial Intelligence for Omics Data: A Systematic Mapping Study","volume":"25","author":"Toussaint P. A.","year":"2023","journal-title":"Briefings in Bioinformatics"},{"issue":"4","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative Clinicopathological and Molecular Analyses of Angioimmunoblastic T\u2010Cell Lymphoma and Other Nodal Lymphomas of Follicular Helper T\u2010Cell Origin","volume":"102","author":"Dobay M. P.","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3324\/haematol.2017.180430","article-title":"Epstein\u2010Barr Virus\u2010Associated Primary Nodal T\/NK\u2010Cell Lymphoma Shows a Distinct Molecular Signature and Copy Number Changes","volume":"103","author":"Ng S. B.","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and Upcoming Treatment Approaches to Common Subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"Moskowitz A. J.","year":"2024","journal-title":"Blood"},{"issue":"10168","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin With Chemotherapy for CD30\u2010Positive Peripheral T\u2010Cell Lymphoma (ECHELON\u20102): A Global, Double\u2010Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz S.","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaoncol.2022.1968","article-title":"Efficacy and Safety of a Pegasparaginase\u2010Based Chemotherapy Regimen vs an L\u2010Asparaginase\u2010Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer\/T\u2010Cell Lymphoma: A Randomized Clinical Trial","volume":"8","author":"Wang X.","year":"2022","journal-title":"JAMA Oncology"},{"issue":"5","key":"e_1_2_12_16_1","article-title":"Peripheral T\u2010 and Natural Killer\u2010Cell Lymphomas: ESMO\u2010EHA Clinical Practice Guideline for Diagnosis, Treatment, and Follow\u2010Up","volume":"9","author":"d'Amore F.","year":"2025","journal-title":"Hema"},{"issue":"2","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101416","article-title":"Genomic and Transcriptomic Profiling of Peripheral T Cell Lymphoma Reveals Distinct Molecular and Microenvironment Subtypes","volume":"5","author":"Huang Y. H.","year":"2024","journal-title":"Cell Reports Medicine"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231173485","article-title":"Epigenetic Targets in B\u2010 and T\u2010Cell Lymphomas: Latest Developments","volume":"14","author":"Ribeiro M. L.","year":"2023","journal-title":"Therapeutic Advances in Hematology"},{"issue":"11","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real\u2010World Efficacy of 5\u2010Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T\u2010Cell Lymphoma","volume":"22","author":"Yoon S. E.","year":"2022","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"16","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined Oral 5\u2010Azacytidine and Romidepsin Are Highly Effective in Patients With PTCL: A Multicenter Phase 2 Study","volume":"137","author":"Falchi L.","year":"2021","journal-title":"Blood"},{"issue":"4","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The Noncanonical Role of EZH2 in Cancer","volume":"112","author":"Huang J.","year":"2021","journal-title":"Cancer Science"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216706","article-title":"EZH2\u2010Mediated Development of Therapeutic Resistance in Cancer","volume":"586","author":"Kaur P.","year":"2024","journal-title":"Cancer Letters"},{"issue":"7","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-23-2582","article-title":"Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T\u2010Cell Lymphoma: Data From the First\u2010In\u2010Human Phase I Study","volume":"30","author":"Song Y.","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108638","article-title":"HDAC Inhibition Results in Widespread Alteration of the Histone Acetylation Landscape and BRD4 Targeting to Gene Bodies","volume":"34","author":"Slaughter M. J.","year":"2021","journal-title":"Cell Reports"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101779","article-title":"Defining Cellular Responses to HDAC\u2010Selective Inhibitors Reveals That Efficient Targeting of HDAC3 Is Required to Elicit Cytotoxicity and Overcome Naive Resistance to Pan\u2010HDACi in Diffuse Large B Cell Lymphoma","volume":"39","author":"Havas A. P.","year":"2024","journal-title":"Translational Oncology"},{"issue":"8","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open\u2010Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T\u2010Cell Lymphoma","volume":"26","author":"Shi Y.","year":"2015","journal-title":"Annals of Oncology"},{"issue":"1","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200160","article-title":"Chidamide Maintenance Therapy for Patients With Peripheral T\u2010Cell Lymphoma: A Multicenter Real\u2010World Analysis","volume":"144","author":"Jiang W.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1430648","article-title":"Clinical Trial: Chidamide Plus CHOP Improve the Survival of Newly Diagnosed Angioimmunoblastic T\u2010Cell Lymphoma","volume":"15","author":"Zong X.","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular Heterogeneity in Peripheral T\u2010Cell Lymphoma, Not Otherwise Specified Revealed by Comprehensive Genetic Profiling","volume":"33","author":"Watatani Y.","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in Patients With Relapsed\/Refractory Peripheral T\u2010Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial","volume":"144","author":"Mehta\u2010Shah N.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"3074.1","DOI":"10.1182\/blood-2024-203290","article-title":"A Multicenter, Open\u2010Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed\/Refractory Nodal T Cell Lymphoma With T Follicular Helper Phenotype","volume":"144","author":"Cwynarski K.","year":"2024","journal-title":"Blood"},{"issue":"26","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A Phase 2 Biomarker\u2010Driven Study of Ruxolitinib Demonstrates Effectiveness of JAK\/STAT Targeting in T\u2010Cell Lymphomas","volume":"138","author":"Moskowitz A. J.","year":"2021","journal-title":"Blood"},{"issue":"8","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot Trial of Ibrutinib in Patients With Relapsed or Refractory T\u2010Cell Lymphoma","volume":"2","author":"Kumar A.","year":"2018","journal-title":"Blood Advances"},{"issue":"5","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/bjh.70458","article-title":"Exploiting ALK Inhibition in Anaplastic Large Cell Lymphoma: Biological Rationale and Therapeutic Integration","volume":"208","author":"Caserta S.","year":"2026","journal-title":"British Journal of Haematology"},{"issue":"6","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2024014745","article-title":"Pediatric Relapsed\/Refractory ALK\u2010Positive Anaplastic Large Cell Lymphoma Treatment and Outcomes in the Targeted\u2010Drug Era","volume":"9","author":"Marks L. J.","year":"2025","journal-title":"Blood Advances"},{"issue":"1","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13045-020-01006-w","article-title":"Novel Targeted Therapies of T Cell Lymphomas","volume":"13","author":"Izykowska K.","year":"2020","journal-title":"Journal of Hematology and Oncology"},{"issue":"9","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 Biology and Therapeutic Targeting: A Historical Perspective Providing Insight Into Future Directions","volume":"7","author":"Weyden C. A.","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10\u2010vcMMAE, an Anti\u2010CD30\u2010Monomethyl Auristatin E Conjugate With Potent and Selective Antitumor Activity","volume":"102","author":"Francisco J. A.","year":"2003","journal-title":"Blood"},{"issue":"18","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN\u201035) in Patients With Relapsed or Refractory Systemic Anaplastic Large\u2010Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro B.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2021-145124","article-title":"The Echelon\u20102 Trial: 5\u2010Year Exploratory Subgroup Analyses of a Randomized, Double\u2010Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts With CD30\u2010Positive Peripheral T\u2010Cell Lymphoma","volume":"138","author":"Horwitz S. M.","year":"2021","journal-title":"Blood"},{"issue":"5","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA Approval Summary: Brentuximab Vedotin in First\u2010Line Treatment of Peripheral T\u2010Cell Lymphoma","volume":"24","author":"Richardson N. C.","year":"2019","journal-title":"Oncologist"},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105693","article-title":"Molecular Heterogeneity of CD30(+) Peripheral T\u2010Cell Lymphoma With Prognostic Significance and Therapeutic Implications: A Retrospective Multi\u2010Centre Study","volume":"115","author":"Huo Y. J.","year":"2025","journal-title":"eBioMedicine"},{"issue":"1","key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR\u2010T Cell Therapy for Cancer: Current Challenges and Future Directions","volume":"10","author":"Zugasti I.","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"9","key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and Immunological Responses After CD30\u2010Specific Chimeric Antigen Receptor\u2010Redirected Lymphocytes","volume":"127","author":"Ramos C. A.","year":"2017","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti\u2010CD30 CAR T Cells as Consolidation After Autologous Haematopoietic Stem\u2010Cell Transplantation in Patients With High\u2010Risk CD30(+) Lymphoma: A Phase 1 Study","volume":"11","author":"Grover N. S.","year":"2024","journal-title":"Lancet Haematology"},{"issue":"1","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1\u2010CAR T Cell Therapy in Peripheral T Cell Lymphoma: A Phase 1\/2 Trial","volume":"31","author":"Cwynarski K.","year":"2025","journal-title":"Nature Medicine"},{"issue":"12","key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","article-title":"ALK Inhibitors Increase ALK Expression and Sensitize Neuroblastoma Cells to ALK.CAR\u2010T Cells","volume":"41","author":"Bergaggio E.","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T\u2010Cell Therapies for T\u2010Cell Malignancies: Does Cellular Immunotherapy Represent the Best Chance of Cure?","volume":"9","author":"Maciocia N.","year":"2025","journal-title":"Blood Advances"},{"issue":"4","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41375-024-02171-4","article-title":"Genomic Features Reveal Potential Benefit of Adding Anti\u2010PD\u20101 Immunotherapy to Treat Non\u2010Upper Aerodigestive Tract Natural Killer\/T\u2010Cell Lymphoma","volume":"38","author":"Chen Z.","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for Relapsed\/Refractory Extranodal NK\/T Cell Lymphoma: A Multicenter, Single\u2010Arm, Phase 2 Trial (ORIENT\u20104)","volume":"6","author":"Tao R.","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115155","article-title":"Anti\u2010PD\u20101 Antibody (Tislelizumab) Combined With Gemcitabine and Oxaliplatin for Extranodal NK\/T\u2010Cell Lymphoma Failing Asparaginase: A Multicenter Phase II Trial","volume":"214","author":"Ding K.","year":"2025","journal-title":"European Journal of Cancer"},{"issue":"16","key":"e_1_2_12_52_1","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating Relapsed\/Refractory Mature T\u2010 and NK\u2010Cell Neoplasms With Tislelizumab: A Multicenter Open\u2010Label Phase 2 Study","volume":"7","author":"Bachy E.","year":"2023","journal-title":"Blood Advances"},{"issue":"16","key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer\/T\u2010Cell Lymphoma (GEMSTONE\u2010201): Results From a Single\u2010Arm, Multicenter, Phase II Study","volume":"41","author":"Huang H.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"e_1_2_12_54_1","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the Treatment of Relapsed or Refractory Extranodal NK\/T\u2010Cell Lymphoma: An Open\u2010Label Phase 2 Study","volume":"136","author":"Kim S. J.","year":"2020","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_55_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T Cell Lymphoma: An Open\u2010Label Phase 2 Study (Gxplore\u2010002)","volume":"14","author":"Shi Y.","year":"2021","journal-title":"Journal of Hematology and Oncology"},{"issue":"1","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-024-01782-8","article-title":"Anti\u2010Metabolic Agent Pegaspargase Plus PD\u20101 Antibody Sintilimab for First\u2010Line Treatment in Advanced Natural Killer T Cell Lymphoma","volume":"9","author":"Xiong J.","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"e_1_2_12_57_1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ajh.26922","article-title":"A Phase II Study of Sintilimab, Anlotinib, and Pegaspargase Sandwiched With Radiotherapy as First\u2010Line Therapy in Patients With Newly Diagnosed, Stage I\u2010II Extranodal Natural\u2010Killer\/T\u2010Cell Lymphoma","volume":"98","author":"Sun P.","year":"2023","journal-title":"American Journal of Hematology"},{"issue":"5","key":"e_1_2_12_58_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.21147\/j.issn.1000-9604.2022.05.01","article-title":"National Guidelines for Diagnosis and Treatment of Malignant Lymphoma 2022 in China (English Version)","volume":"34","author":"Health Commission Of The People's Republic Of China N","year":"2022","journal-title":"Chinese Journal of Cancer Research"},{"issue":"17","key":"e_1_2_12_59_1","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid Progression of Adult T\u2010Cell Leukemia\/Lymphoma as Tumor\u2010Infiltrating Tregs After PD\u20101 Blockade","volume":"134","author":"Rauch D. A.","year":"2019","journal-title":"Blood"},{"key":"e_1_2_12_60_1","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2024-200751","article-title":"EBV\u2010Infected NKTCL Upregulated MHC\u2010II Imprinted T Cell Exhaustion by Interacting With LAG3","volume":"144","author":"Zhang S.","year":"2024","journal-title":"Blood"},{"issue":"42","key":"e_1_2_12_61_1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx6877","article-title":"Cooperative Role of Distinctive TP53 and PTEN Combined Loss in the Peripheral T Cell Lymphoma\u2010GATA3 Molecular Subgroup","volume":"11","author":"Lone W. G.","year":"2025","journal-title":"Science Advances"},{"issue":"5","key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41375-025-02563-0","article-title":"Discrete Genetic Subtypes and Tumor Microenvironment Signatures Correlate With Peripheral T\u2010Cell Lymphoma Outcomes","volume":"39","author":"Suehara Y.","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_63_1","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2024.100048","article-title":"Precise Diagnosis and Treatment for Peripheral T\u2010Cell Lymphomas: From Pathogenic Mechanisms to Innovative Approaches","volume":"2","author":"Qiu Y.","year":"2024","journal-title":"Innovation Medicine"},{"issue":"36","key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.21.02707","article-title":"Gene Expression Signatures for the Accurate Diagnosis of Peripheral T\u2010Cell Lymphoma Entities in the Routine Clinical Practice","volume":"40","author":"Amador C.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"e_1_2_12_65_1","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/bloodadvances.2018018754","article-title":"Microenvironmental Immune Cell Signatures Dictate Clinical Outcomes for PTCL\u2010NOS","volume":"2","author":"Sugio T.","year":"2018","journal-title":"Blood Advances"},{"issue":"2","key":"e_1_2_12_66_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/0008-5472.CAN-25-0881","article-title":"Multiomics Profiling of T\u2010Cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery","volume":"86","author":"Ianevski A.","year":"2026","journal-title":"Cancer Research"},{"issue":"4","key":"e_1_2_12_67_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102029","article-title":"A Patient\u2010Derived T Cell Lymphoma Biorepository Uncovers Pathogenetic Mechanisms and Host\u2010Related Therapeutic Vulnerabilities","volume":"6","author":"Fiore D.","year":"2025","journal-title":"Cell Reports Medicine"},{"issue":"2","key":"e_1_2_12_68_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103798","article-title":"Machine Learning for Multi\u2010Omics Data Integration in Cancer","volume":"25","author":"Cai Z.","year":"2022","journal-title":"iScience"},{"issue":"1150","key":"e_1_2_12_69_1","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20230211","article-title":"Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration","volume":"96","author":"Wei L.","year":"2023","journal-title":"British Journal of Radiology"},{"issue":"6","key":"e_1_2_12_70_1","doi-asserted-by":"crossref","DOI":"10.3390\/genes16060648","article-title":"A Comprehensive Review of Deep Learning Applications With Multi\u2010Omics Data in Cancer Research","volume":"16","author":"Sartori F.","year":"2025","journal-title":"Genes"},{"issue":"5","key":"e_1_2_12_71_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","article-title":"Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead","volume":"1","author":"Rudin C.","year":"2019","journal-title":"Nature Machine Intelligence"},{"issue":"1","key":"e_1_2_12_72_1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41746-025-01958-8","article-title":"Comparison of SHAP and Clinician Friendly Explanations Reveals Effects on Clinical Decision Behaviour","volume":"8","author":"Hur S.","year":"2025","journal-title":"npj Digital Medicine"},{"issue":"1","key":"e_1_2_12_73_1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2024-201683","article-title":"Machine Learning\u2010Based Approach to Improve Classification and Diagnostics of Peripheral T\u2010Cell Lymphomas","volume":"144","author":"Sobol A.","year":"2024","journal-title":"Blood"},{"key":"e_1_2_12_74_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1732079","article-title":"Artificial Intelligence\u2010Enabled Multi\u2010Omics Biomarkers for Immune Checkpoint Blockade: Mechanisms, Predictive Modeling, and Clinical Translation","volume":"17","author":"Wang X.","year":"2026","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"e_1_2_12_75_1","doi-asserted-by":"crossref","first-page":"35606","DOI":"10.1038\/s41598-025-18148-x","article-title":"Predicting One\u2010Year Overall Survival in Patients With AITL Using Machine Learning Algorithms: A Multicenter Study","volume":"15","author":"Huang X.","year":"2025","journal-title":"Scientific Reports"},{"issue":"3","key":"e_1_2_12_76_1","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.15859","article-title":"Comparison of the NCCN\u2010IPI, the IPI and PIT Scores as Prognostic Tools in Peripheral T\u2010Cell Lymphomas","volume":"186","author":"Ellin F.","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"1","key":"e_1_2_12_77_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12964-025-02438-y","article-title":"Clinical Implications of ctDNA\u2010Based Minimal Residual Disease Detection in Newly Diagnosed Peripheral T\u2010Cell Lymphoma: A Single\u2010Center Cohort Study","volume":"23","author":"Liang J. H.","year":"2025","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"2","key":"e_1_2_12_78_1","doi-asserted-by":"crossref","DOI":"10.3390\/biom16020271","article-title":"Challenges and Opportunities in Multi\u2010Omics Data Acquisition and Analysis: Toward Integrative Solutions","volume":"16","author":"Hemme C. L.","year":"2026","journal-title":"Biomolecules"},{"issue":"12","key":"e_1_2_12_79_1","first-page":"4021","article-title":"Distinctive Genomic Features of Human T\u2010Lymphotropic Virus Type 1\u2010Related Adult T\u2010Cell Leukemia\u2010Lymphoma in Western Populations","volume":"109","author":"Myers C. S.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_12_80_1","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2026.1749527","article-title":"Explainable AI in Healthcare: A Systematic Review of XAI Use Cases in Imaging, Diagnostics, and Rehabilitation","volume":"9","author":"Aravindkumar A.","year":"2026","journal-title":"Frontiers in Artificial Intelligence"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:56:54Z","timestamp":1788929814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":79,"alternative-id":["10.1111\/ejh.70313"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70313","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70313"}}